v3.26.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 27, 2026
Jun. 28, 2025
Mar. 28, 2026
Segment Reporting [Line Items]      
Total net revenues $ 339,380 $ 321,394  
Cost of goods sold 136,577 129,150  
Selling, general and administrative 118,941 110,719  
Research and development 16,200 16,261  
Operating income 57,458 53,872  
Amortization of acquired assets 10,204 11,392  
Interest and other expense, net (9,884) (8,703)  
Income before provision for income taxes 47,574 45,169  
Net revenues 339,380 321,394  
Depreciation and amortization 27,111 28,758  
Total long-lived assets 303,778   $ 305,761
United States      
Segment Reporting [Line Items]      
Net revenues 257,844 242,404  
Total long-lived assets 223,004   224,699
Japan      
Segment Reporting [Line Items]      
Net revenues 12,858 13,648  
Total long-lived assets 882   916
Europe      
Segment Reporting [Line Items]      
Net revenues 45,529 40,882  
Total long-lived assets 32,293   32,080
Rest of Asia      
Segment Reporting [Line Items]      
Net revenues 20,163 21,648  
Total long-lived assets 30,010   30,833
Other      
Segment Reporting [Line Items]      
Net revenues 2,986 2,812  
Total long-lived assets 17,589   17,233
Apheresis      
Segment Reporting [Line Items]      
Total net revenues 191,318 181,736  
Net revenues 191,318 181,736  
Depreciation and amortization 13,631 13,912  
Total long-lived assets 244,089   246,042
Apheresis | Plasma      
Segment Reporting [Line Items]      
Net revenues 155,524 145,074  
Apheresis | Other      
Segment Reporting [Line Items]      
Net revenues 35,794 36,662  
MedSurg      
Segment Reporting [Line Items]      
Total net revenues 148,062 139,658  
Net revenues 148,062 139,658  
Depreciation and amortization 13,480 14,846  
Total long-lived assets 59,689   $ 59,719
MedSurg | Interventional Technologies      
Segment Reporting [Line Items]      
Net revenues 59,942 58,483  
MedSurg | Blood Management Technologies      
Segment Reporting [Line Items]      
Net revenues 88,120 81,175  
Operating Segments | Apheresis      
Segment Reporting [Line Items]      
Cost of goods sold 84,131 75,865  
Selling, general and administrative 44,264 39,880  
Research and development 6,378 6,816  
Operating income 56,545 59,175  
Operating Segments | MedSurg      
Segment Reporting [Line Items]      
Cost of goods sold 50,368 50,216  
Selling, general and administrative 65,160 62,323  
Research and development 9,820 8,742  
Operating income 22,714 18,377  
Corporate      
Segment Reporting [Line Items]      
Operating income 57,458 53,872  
Amortization of acquired assets 10,204 13,828  
Integration and transaction costs (2,719) (2,682)  
Restructuring and restructuring related costs 2,258 1,324  
Digital transformation costs 6,163 5,355  
Other $ (457) $ (491)